TrialJournal of managed care & specialty pharmacy2021

Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis.

Bob G Schultz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.